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Abstract
Background—Women younger than 45 years old have lower rates of breast cancer, but higher 
risk of recurrence and mortality after a cancer diagnosis. African American women are at risk for 
early onset and increased mortality; Ashkenazi Jewish women are at risk for genetic mutations 
leading to breast and ovarian cancer. Although younger women are encouraged to talk to doctors 
about their family history, little is known about these discussions.
Materials and Methods—In 2015, 167 women aged 18–44 years participated in 20 focus 
groups segmented by geographic location, age, race/ethnicity, and family history of breast and 
ovarian cancer. Transcript data were analyzed using NVivo 10 software.
Results—Although the majority of women talked to their doctor about breast and ovarian cancer, 
these conversations were brief and unsatisfying due to a lack of detail. Topics included family 
history, breast cancer screening, and breast self-examination. Some women with and without 
family history reported that healthcare providers offered screening and early detection advice 
based on their inquiries. However, few women took action or changed lifestyle behaviors with the 
intent to reduce risk as a result of the conversations.
Conclusions—Conversations with young women revealed missed opportunities to: enhance 
patient-provider communication and increase knowledge about breast cancer screening and 
surveillance for higher risk patients. Physicians, allied health professionals, and the public health 
community can better assist women in getting accurate and timely information about breast and 
ovarian cancer, understanding their family history to determine risk, and increasing healthy 
behaviors.
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Introduction
Breast cancer affects women of all ages, with most cases diagnosed in women older than 50 
years.1 While women younger than 45 years only account for <10% of all cases,1 their 
occurrences are often accompanied by higher risk of recurrence and death, compared to 
older women.2,3 This is true for African American women who have been identified as 
having increased prevalence at younger ages and increased mortality rates from breast 
cancer.4–6 Breast cancer at younger ages could be indicative of genetic mutations like 
BRCA1/2, which are associated with increased susceptibility to hereditary breast and 
ovarian cancer (HBOC).7,8 While the risk of having these mutations occurs in about 1 in 400 
people in the general population, women of Ashkenazi Jewish descent are at higher risk.9,10 
Recent studies have also reported higher-than-expected frequencies of BRCA mutations 
among young (<45 years) African American women living with breast cancer.11
Younger women can talk to their doctors about their family history of breast and ovarian 
cancer and associated risk, ways to reduce risk (e.g., breast feeding, limiting alcohol, 
maintaining a healthy weight, and avoiding exposure to carcinogens and radiation), and 
recommendations for genetic counseling and/or testing. Genetic counseling can help women 
understand their hereditary breast cancer risk and determine whether genetic testing is 
warranted to identify genetic mutations with hereditary links.12 Younger women determined 
to be at higher risk may also benefit from discussions of early detection strategies through 
advanced screening or other medical interventions.
Unfortunately, existing research has identified several challenges to effective patient and 
provider communication about breast and ovarian cancer and poor uptake of action-oriented 
outcomes, including referral to genetic counseling and testing. These challenges include the 
following: lack of primary care providers (PCPs) knowledge about HBOC and limited 
experience in referring women for genetic counseling13–15; poor systematic collection of 
family history data16,17; provider difficulty in communicating genetic risk18–20; and poor 
patient understanding regarding HBOC, the genetic counseling and testing process, and the 
meaning of genetic testing results.21–24 Some interventions to address these challenges 
include continuing medical education for providers and the inclusion of nurses, allied health 
professionals, and patient navigators in the delivery of communication. However, the 
evidence regarding effectiveness of these interventions has not been widely examined 
regarding breast cancer communication between young women and their providers.
While the aforementioned challenges have been examined, limited information exists 
regarding aspects of communication between providers and patients, including the types of 
healthcare providers (HCPs) with whom young women are talking about breast and ovarian 
cancer; catalysts for these conversations; topics discussed; tone and satisfaction of the 
conversations; and actions taken as a result. In addition, these factors have not been 
evaluated and compared across groups of women with and without a family history of breast 
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and ovarian cancer or those from specific racial/ethnic backgrounds which may predispose 
them to higher risk of breast cancer occurrence or breast cancer-related mortality. Our study 
examines these underexplored factors regarding patient and HCP communication about 
breast and ovarian cancer, related risk, and actions that can be taken to lower risk or detect 
breast cancer earlier in women at higher risk.
Materials and Methods
The Centers for Disease Control and Prevention’s (CDC) “Bring Your Brave” (BYB) 
campaign25 provides information and resources about breast cancer and related risk for 
women younger than age 45 by sharing real stories about young women affected by breast 
cancer. As part of a larger qualitative study for this campaign,25 data from young women 
were collected during focus groups conducted in five U.S. cities over 1 month (Chicago, 
New York City, Birmingham, Sacramento, and Phoenix). Twenty focus groups were 
conducted, in part, to explore beliefs and perceptions regarding communication with HCPs 
about breast and ovarian cancer. Focus groups were conducted with women aged 18–44 
years and segmented by race/ethnicity (Ashkenazi Jewish, African American, or other 
“general population/other racial or ethnic groups”), age (18–29 years vs. 30–44 years), and 
by any reported first or second degree relative, maternal, and/or paternal family history of 
breast or ovarian cancer (history vs. no history; Table 1).
Professional recruiting service firms arranged logistics and participants for the focus groups. 
All participants were screened to ensure respondents met inclusion criteria and to ensure 
heterogeneous demographic parameters (Table 2). Groups were then stratified by age, race/
ethnicity, and family history (Table 1). Institutional Review Board exemption and Office of 
Management and Budget approval were received from the CDC and Oak Ridge Associated 
Universities. Written and verbal consent were obtained from participants during the 
screening process and before focus groups. Participants who met inclusion criteria were 
enrolled in the study and received an incentive ($75).
Focus groups lasted 2 hours and were conducted by professional female moderators with 
relevant experience in cancer/chronic disease. All moderators used semistructured 
moderator’s guides developed by the study team. Moderators were matched to focus groups 
for which they self-identified as the same race/ethnicity as participants. Trained research 
staff observed focus groups in person, via a two-way mirror, and through online streaming. 
Focus group discussions were audio recorded and transcribed.
Analysis
Two team members (B.S. and B.W.) reviewed transcripts for accuracy and completeness 
against discussion notes and audio recordings. Final transcripts were uploaded to QSR 
International’s NVivo 10 software for analysis. Reviewers trained in qualitative thematic 
analysis reviewed the data and developed a codebook. Using the codebook, three researchers 
coded transcripts independently. A coding comparison query was run to determine 
agreement between coders and to test for quality assurance and accuracy (reliability rate 
≥75%). Researchers analyzed coded responses to identify thematic differences and 
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similarities in perceived participant and HCP communication between ethnic and racial 
groups, those with presence or absence of family history, and younger and older age groups.
Results
Sample characteristics
Of 167 total participants, 41% lived in the western census26 region (n = 69); 30% lived in 
the midwest (n = 50), 19% lived in the south (n = 32), and 10% lived in the northeast (n = 
16) of the United States. Forty-one percent self-identified as being from racial/ethnic groups 
other than African American and Ashkenazi Jewish (“general population”; n =69), 39% 
were African American (n =65), and 20% described being of Ashkenazi Jewish descent (n = 
33). About half were under 29 years old (n = 84) and the majority of participants reported 
having one or more relatives diagnosed with breast and/or ovarian cancer (n =89; Table 1). 
While participants in family history groups were not required to have an affected relative 
diagnosed at a young age (under 50 years), several family history group participants did self-
disclose having a female relative who was diagnosed with breast cancer at a young age.
Occurrence of patient-provider communication regarding breast and ovarian cancer and 
related risk
Responses are outlined below. Select responses (transcribed quotations) are available in 
Table 3. Alphanumeric designations in the text refer to relevant quotation numbers.
Across all segments (age, ethnicity, and family history), most women reported 
communicating with their HCPs about breast and ovarian cancer. Independent of race/
ethnicity, women with and without a family history mentioned that women without a family 
history of breast or ovarian cancer would be less likely to need or want to talk to HCPs about 
breast or ovarian cancer (Table 3, c1, c2). While not the majority, some women in general 
population groups with a family history endorsed not wanting to discuss breast and ovarian 
cancer with their HCPs, despite possible risk.
Most women, across all focus group segments, reported having regular annual appointments 
with a HCP at which conversations about breast and ovarian cancer were most likely to 
occur. Conversations about breast and ovarian cancer were more likely to occur with 
obstetricians and gynecologists (OB/GYN) than with other types of PCPs. In addition to 
OB/GYNs and PCPs, women also reported speaking with nurses, herbalists, midwives, 
medical staff working for health insurance companies, and counseling specialists working at 
doctor’s offices.
Women with a family history described being the primary initiators of conversations 
regarding breast and ovarian cancer, but agreed that HCPs also initiated these conversations. 
Women without a family history reported that they did not routinely initiate communication 
as “it was not something they needed or wanted to talk about,” given that no close relative 
had been diagnosed. Differences in being the primary initiator were also seen based on age 
and race/ethnicity. Women aged 30–44 years were more likely to report HCPs initiated 
conversation, while women 18–29 years endorsed being initiators. African American women 
were slightly more likely to report initiating conversations with their HCPs compared to 
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respondents who identified as Ashkenazi Jewish or were part of other racial and ethnic 
groups.
Catalysts and barriers for patient-provider communication
Catalysts for communication. While most women, across all segments, communicated with 
their HCPs about breast cancer and ovarian cancer, the majority described these 
conversations as brief and lacking detail. Several women initiated conversations with HCPs 
after experiencing symptoms or health concerns they perceived to be related to breast and 
ovarian cancer, including lumps, uneven breast development, back pain, and chest acne. 
Most women with a family history of breast or ovarian cancer, independent of race/ethnicity, 
agreed that having a family history prompted them to speak with their HCPs (Table 3, c3, c4, 
c5). The majority of women across group segments agreed that they answer questions about 
family history of any medical illness on appointment intake forms. However, most women 
with and without family history of breast and ovarian cancer agreed that the forms did not 
prompt much in-depth conversation with their HCP about breast or ovarian cancer or related 
risk. Instead, women with a family history mentioned that more in-depth discussion with a 
provider might occur only after a woman is referred for screening by their HCP and if she 
receives an abnormal screening test result.
Barriers to communication—Some women reported avoiding communication with 
HCPs regarding breast and ovarian cancer. Ashkenazi Jewish women also reported not 
initiating conversations during annual doctors’ visits due to lack of concern about the 
diseases, an assumption that the “HCP would bring it up if it was important,” and limited 
consultation time with the doctor (Table 3, c6, c7). Some women from general population 
groups also described not wanting to discuss concerns about breast and ovarian cancer with 
their HCPs despite understanding risk, due to fear of getting tested and diagnosed with these 
cancers (Table 3, c8).
Topics discussed during patient-provider conversations
Breast health topics women most frequently mentioned discussing with their HCPs were 
related to clinical breast examination and recommended mammography screening ages, 
family history, and breast self-examination (BSE).
Clinical breast examination and recommended screening ages—Most women 
with a family history of breast and/ or ovarian cancer and a few without reported speaking 
with their HCPs about clinical breast examinations and the recommended age to begin 
mammography. The reported HCP recommended age of initiation among women with a 
family history varied by race/ethnicity (African American women = 23–42 years; Ashkenazi 
Jewish women = 30–35 years; and women in the general population groups = 40–50 years).
Several 30- to 44-year-old African American women with a family history endorsed talking 
to their HCP about mammography and receiving a mammogram before age 40 years. 
Women in this group who received a mammogram expressed feeling “happy” with their 
decision to get screened. Most women in this group, who did not receive a mammogram, 
reported frustration when they were advised to wait, even after expressing a strong desire to 
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have a mammogram. Some women in this group felt they were being prevented from doing 
what would be best for their health (Table 3, c9, c10). In some cases, they acknowledged 
questioning their HCPs judgment or concern for them as a patient. Reasons they were 
advised to wait ranged from being too young, the procedure not being covered by insurance 
(at their age), and being informed that they “did not need one.”
Family history and health concerns—Few women with a family history reported 
having conversations pertaining to counseling about the BRCA gene and/or genetic testing. 
Some Ashkenazi Jewish women without a family history mentioned that providers inquired 
about their ethnicity, informed them of associated risk for genetic diseases (e.g., Tay-Sachs), 
and suggested genetic testing to identify genetic mutations for diseases other than breast and 
ovarian cancer. Overall, HBOC risk was not usually brought up during these discussions 
(Table 3, c11). While the majority of Ashkenazi Jewish women stated that their HCPs were 
aware of their ethnic background, some 30–44 years old without a family history expressed 
frustration or concern that their HCPs never discussed HBOC risks specific to their 
Ashkenazi Jewish heritage. Women in this group felt that their HCPs should be aware of 
their increased risk of HBOC and discuss these concerns with them (Table 3, c12, c13).
Breast self-examination—Many women, across all groups, reported that their HCPs 
regularly taught and encouraged them to conduct BSE.
Other discussion topics—A few women mentioned discussing ovarian cancer risk and 
insurance coverage for breast cancer screening with their HCPs. Notably, few women in any 
of the focus group segments reported discussing preventive health behaviors related to breast 
or ovarian cancers with their HCPs.
Tone of conversations and related patient satisfaction
Several women across focus group segments described the tone of conversations with HCPs 
as “pleasant,” “comfortable,” “easy,” “reassuring,” and “casual/laid back.” While a positive 
tone to conversations with their HCPs was reported, women, especially those who were aged 
30–44 years and those with a family history, regularly reported dissatisfaction with the 
content or outcomes of HCP conversations describing communication as “matter of fact” 
and “surface/basic.”
Family history—Many women with a family history (independent of race/ethnicity) felt 
their concerns were not always appropriately addressed by HCPs because of their young age 
(Table 3, c14, c15). In addition, some women with a family history felt that they did not get 
credible or satisfactory information or explanation of test results from their HCPs, which left 
them “frustrated” and/or “looking to other HCPs or sources for health information” (Table 3, 
c16, c17).
Age—The amount of time allocated for patient visits was commonly discussed as a reason 
for dissatisfaction, among 30-to 44-year-old women. These women felt the time constraints 
on HCP visits prevented them from having their health concerns addressed in a thorough and 
timely manner (Table 3, c18, c19). Only a few women expressed that their HCPs took time 
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to answer all their questions and address any concerns they had regarding breast and ovarian 
cancer-related topics.
Actions taken based on conversations with HCPs and reasons for inaction
Overall, few women mentioned actions they had taken as a result of breast cancer and 
ovarian cancer discussions with their HCPs. Some women, including those without a family 
history, reported that their HCPs offered screening and early detection advice based on their 
inquiries, but advice regarding age of screening initiation varied by race/ethnicity. Some 
women also described getting a mammogram or doing BSE, as recommended by their HCPs 
(Table 3, c20, c21, c22). Few women reported engaging in preventive behaviors (e.g., 
exercise and healthy eating), researching health topics, and initiating conversations with 
family members after discussing breast and/or ovarian cancer with their HCP.
Ashkenazi Jewish women aged 30–44 years discussed actions they had not taken or would 
not take due to inability or unwillingness. Some women in this group mentioned that they 
had not received a mammogram because they were breastfeeding. Others who were advised 
to get genetic testing did not do so because they were only given pamphlets and educational 
materials by their provider without a more robust conversation about testing details and 
rationale, or they did not see the purpose in getting genetic testing if they were not willing to 
take surgical preventive measures, including prophylactic mastectomy (Table 3, c23).
Discussion
This analysis explored communication between young women and their HCPs regarding 
breast and ovarian cancer and hereditary risk. The majority of women in the study reported 
annual preventive care doctors’ visits with a PCP or OB/GYN. In comparison, only 41% of 
women aged 18–29 years and 45% of women aged 30–49 years attend annual preventive 
care visits with PCPs or OB/GYNs.27
While many women reported discussing breast and/or ovarian cancer during routine 
wellness visits, these conversations were often described as containing limited discussion 
about hereditary risk or prevention. The lack of detailed information provided may be a 
function of factors reported in our study, including women without a family history of breast 
and/or ovarian cancer feeling less concerned or having no desire to speak with a HCP about 
related topics, limited time during doctors’ visits, and fear of discussing cancer and related 
risk. High levels of dissatisfaction were reported regarding the amount of tailored 
information shared by HCPs, especially among women with a family history. As several 
women in our study reported having a relative diagnosed with breast and/or ovarian cancer 
before age 50 years, women in these groups may have elevated risk and a subsequent need 
for more intensive discussions regarding screening, genetic counseling, and genetic testing 
in accordance with care guidelines and recommendations12,28 (when indicated).
Across groups, women reported that both they and their providers initiated discussions. 
However, family history of breast and ovarian cancer was a catalyst for patient-initiated 
communication with a provider. This is consistent with previous research showing women 
with a family history are more interested in initiating discussions about risk, genetic 
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counseling, and testing.29,30 Experiencing symptoms (e.g., lumps and pain) or health 
concerns, in addition to having an abnormal screening test, were also reported catalysts for 
patient-initiated communication.
African American women and women aged 18–29 years were more likely to be the 
initiators, while HCPs primarily initiated conversations with women aged 30–44 years. As 
the incidence of breast and ovarian cancer is rare among women who are under the age of 29 
years1 and many breast cancer recommendations pertain to women who are older, it is 
possible that providers do not routinely initiate detailed discussions about breast and ovarian 
cancer given a number of other competing topics that are often covered during the standard 
medical visit (13–16 minutes).31 The onus for initiating discussions about breast and ovarian 
cancer, risk, and prevention may then fall on women who are under the age of 29 years. In 
addition, our finding that African American women were slightly more likely to initiate 
conversations with their HCPs (compared to respondents from Ashkenazi Jewish or general 
population groups) was encouraging given that women in this racial group are at higher risk 
for late-stage diagnosis and poorer outcomes when diagnosed.4–6
Discussion topics
Women in our study talked to their HCPs about family history and hereditary health 
concerns, clinical breast examinations and recommended screening ages, and BSE. While 
completing family history intake forms at doctors’ visits may have prompted women and 
their providers to discuss breast and ovarian cancer, these reported conversations largely did 
not address hereditary risk or BRCA screening for individuals with a family history of 
cancer.12 While providers may be aware of BRCA testing and counseling, research has 
shown that few providers consistently recognize family history patterns as appropriate 
indications of the need for BRCA testing, leading to poor referral rates and, possibly, limited 
communication with patients regarding this topic.32 In the case of hereditary risk among 
Ashkenazi Jewish women, providers may also be more aware of genetic risk for diseases 
like Tay-Sachs and less aware of risks for HBOC related to BRCA1/2.
Regarding discussions about breast cancer screening, women with family history more often 
reported speaking to their HCP about the age they should receive a mammogram, possibly 
due to heightened awareness of potential risks for HBOC. Among women with a family 
history of breast or ovarian cancer, differences in information provided by HCPs about the 
age at which to first receive a mammogram varied by race/ethnicity. It is possible that 
African American (vs. those in the general population) women were informed about starting 
mammography at younger ages by their HCP due to heightened awareness or perceived risk 
of late-stage diagnosis and BRCA genetic mutations, leading to conversations about 
mammography at younger ages. African American women aged 30–44 years with a family 
history endorsed feeling happy after receiving a mammogram before age 40 years as a result 
of having a conversation with their HCP. However, some women in this group also reported 
frustration at not receiving a mammogram after their HCP discouraged them from getting 
screened before age 40 years because they were “too young,” the procedure was not covered 
by insurance (at their age), or other undisclosed reasons. Consistent with previous literature, 
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it is possible that HCPs may discourage patients from voicing their concerns, expectations, 
or requests for more information,33 if the HCP does not feel that screening is indicated.
In all focus group segments, many women mentioned that their HCPs taught and encouraged 
them to conduct BSE. While existing guidelines do not frame determinations regarding BSE 
for high risk women who are not yet recommended to start mammographic screening due to 
age, United States Preventive Services Task Force does recommend against teaching BSE 
for all women.28
Finally, patient-provider conversations reportedly lacked discussion regarding preventive 
health behaviors associated with breast and ovarian cancer risk reduction. This was not 
surprising given that research showing 82% of OB/GYN visits and 74% of visits to PCPs 
among women is not inclusive of counseling regarding obesity, exercise, tobacco use or 
exposure, or diet.27 Health behavior counseling and related interventions are an important 
mechanism to address prevalent health-related behaviors in clinical settings. Subsequently, 
HCPs serve an important and integral role in providing counseling and motivating their 
patients in adopting health behavior changes.34
Satisfaction with conversations and subsequent actions taken
Consistent with previous studies,35 women were largely dissatisfied with their provider 
discussions due to lack of time during the visit, feeling discounted due to their young age, 
and the perception that information provided by their HCP was not credible or satisfactory. 
Women with family history reported feeling discounted due to their age, despite provider 
recommendations12 to screen women with a family history tool designed to identify family 
history associated with increased risk BRCA1/2 genetic mutation. Few women took actions 
to reduce breast and ovarian cancer risk, engaged in preventive methods, sought additional 
knowledge about related topics, or received genetic counseling or testing. HCP 
communication and recommendations have been associated with increased interest in and 
uptake of genetic counseling and testing among certain groups of women.30,36 Limited 
action taken among women in our study may reflect the dearth of received information about 
genetic counseling and testing during their HCP conversations.
Strengths and limitations
This study adds new perspectives to the research in this area, including examining 
perceptions regarding how often communication occurs between HCPs and their patients 
who are 18 through 44 years, satisfaction with topics discussed, and any actions taken 
among those women. The study also uniquely examines respondent communication patterns 
segmented by age, race/ethnicity, and existence of family history of breast and ovarian 
cancer. The study sample size is larger than average for qualitative studies, and women in the 
study represented diversity in economic status, education, marital and parental status, and 
geographic location. However, results are still based on a small sample of recruited 
respondents under age 45 years and may not represent the views of women over the age of 
45 years or those with a personal history of breast and ovarian cancer. This study did not 
formally assess participant cancer risk, making actual risk of participants unknown. The 
study also excluded women who received genetic testing or counseling and, therefore, may 
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have been recognized by a HCP as potentially high risk. However, the study’s intent was to 
examine provider communication and informational needs among women who might be at 
elevated risk based on their family history and who had not received genetic testing or 
counseling. This study, therefore, provides novel findings which can be used to adapt and 
develop content for educational interventions such as the CDC’s BYB campaign for this 
specific group of women.
Conclusions
Although women access healthcare services regularly, HCPs may be missing opportunities 
for providing counseling on breast and ovarian cancer risks and preventive health behaviors. 
While interventions37–39 have been designed to support HCPs in offering evidence-based 
care and guidance and improving patient health literacy, their effectiveness has not routinely 
been evaluated among young women and those who may be at increased risk for breast and 
ovarian cancer. HCPs may benefit from additional training regarding communication with 
patients, especially those under 45 years and/or with a family history of breast and ovarian 
cancer, about risk, prevention, and genetic counseling and appropriate testing. In addition, 
women may benefit from receiving tailored information and educational materials about 
these topics from their HCP and/or other trusted sources.25 As HCPs are continually tasked 
with addressing several health-related topics during brief medical visits, increased 
engagement of nurses, genetic counselors, patient navigators, and other allied health 
professionals may be important in providing more robust discussions with patients. 
Providing all women, including younger women, high-quality and up-to-date information 
about their breast and ovarian cancer risk is imperative. This requires sufficient patient and 
provider engagement and communication about overall risk, preventive health behaviors, 
and screening and surveillance options for women at increased risk.
CDC’s BYB campaign25 informs young women about their risk for breast and ovarian 
cancer and may improve their knowledge and awareness about HBOC and preventive health 
behaviors. Results from this study will be used to inform campaign efforts and 
communication strategies.
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Table 1
Focus Group Segmentation Strategy
Audience segment
Family history of breast or ovarian cancer
Focus group location (one group per location)Yes (n) No (n)
Ashkenazi Jewish women ages 18–29 years 9 — New York City
— 9 Chicago
Ashkenazi Jewish women ages 30–44 years 9 — Chicago
— 7 New York City
African American women ages 18–29 years 8 — Birmingham
9 — Chicago
— 7 Birmingham
— 6 Chicago
African American women ages 30–44 years 9 — Birmingham
9 — Chicago
— 8 Birmingham
— 9 Chicago
General population ages 18–29 years 9 — Sacramento
9 — Phoenix
— 9 Sacramento
— 9 Phoenix
General population ages 30–44 years 9 — Sacramento
9 — Phoenix
— 6 Sacramento
— 9 Phoenix
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Table 2
Focus Group Inclusion and Exclusion Criteria
Inclusion criteria Exclusion criteria Within group characteristics
• Female gender
• 18–44 years of age
• No history of breast or ovarian 
cancer
• No history of undergoing genetic 
counseling or testing regarding 
cancer-related concerns
• Own a smart phonea
• Use of Internet for more than 2 
hours each weeka
• African American/Black race for 
segmented groups in 
Birmingham and Chicago (Table 
1)
• Ashkenazi Jewish for segmented 
groups in New York and Chicago 
(Table 1)
• Nonfemale gender
• 45 years of age and older Current or 
past diagnosis of breast or ovarian 
cancer
• Undergone genetic counseling with a 
licensed genetic counselor regarding 
cancer-related concerns
• Undergone genetic testing related to 
cancer or your risk for developing 
cancer
• Did not own a smart phonea
• Did not use the Internet for at least 2 
hours each weeka
• Employees or contractors for public 
health, like the CDC, local or state 
health department, or other public 
health organization
• Employed or contracted as Medical 
professional
Focus group participants had a mix 
of heterogeneous characteristics, 
including:
• Education level,
• Income,
• Marital status,
• Parental status.
a
Inclusion and exclusion criteria selected as data collected were also used to inform the “Bring Your Brave” campaign.25
CDC, Centers for Disease Control and Prevention.
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ga
in
 to
da
y, 
m
y 
pr
im
ar
y 
ca
re
, a
nd
 sh
e 
fe
lt 
it,
 a
nd
 sh
e 
go
es
 ‘I
t’s
 p
re
tty
 o
bv
io
us
 th
at
 it
’s
 th
er
e,
 so
 I 
do
n’
t 
kn
ow
 w
hy
 sh
e 
di
dn
’t 
kn
ow
’.
 Y
o
u
 k
no
w
,
 
it 
m
ad
e 
m
e 
m
ad
 b
ec
au
se
 y
ou
 g
o 
in
, a
nd
 y
ou
 
m
ak
e 
th
is 
ap
po
in
tm
en
t, 
an
d 
yo
u 
ta
ke
 ti
m
e 
of
f w
o
rk
 to
 d
ed
ic
at
e 
to
 fi
nd
 o
ut
 a
nd
 g
et
 
an
sw
er
s 
an
d 
do
 w
ha
t y
ou
 n
ee
d 
to
 d
o 
to
 a
sk
 q
ue
sti
on
s o
r w
ha
te
v
er
,
 
an
d 
it’
s l
ik
e 
th
os
e 
ar
e 
yo
ur
 1
5 
m
in
ut
es
.”
Ye
s
G
en
er
al
 p
op
ul
at
io
n
30
–4
4
Sa
cr
am
en
to
(c1
8) 
“If
 I f
ee
l a
 pa
in 
an
d s
om
eth
ing
’s 
wr
on
g w
ith
 m
e, 
or 
wh
ate
v
er
,
 
I c
al
l m
y 
do
ct
or
 to
 
m
ak
e 
an
 a
pp
oi
nt
m
en
t. 
Yo
u
 (d
oc
tor
) c
an
’t 
see
 m
e f
or 
thr
ee
 m
on
ths
? I
 ca
n d
rop
 de
ad
 in
 
th
re
e 
m
on
th
s. 
I c
an
 d
ro
p 
de
ad
 to
m
or
ro
w
.
 
W
ha
t a
m
 I 
su
pp
os
ed
 to
 d
o?
 D
on
’t 
te
ll 
m
e 
to
 g
o 
to
 th
e 
em
er
ge
nc
y 
ro
om
. T
he
y’
re
 g
en
er
al
. T
he
y’
re
 n
ot
 g
oi
ng
 to
 d
o 
an
yt
hi
ng
. [
the
 
em
er
ge
nc
y 
ro
om
 d
oc
to
r w
ill
 sa
y]
 ‘M
ak
e 
an
 a
pp
oi
nt
m
en
t w
ith
 y
ou
r d
oc
to
r. 
I d
id
’. 
It’
s n
ot
 
fo
r t
hr
ee
 m
on
th
s.”
Ye
s
A
fri
ca
n 
A
m
er
ic
an
30
–4
4
Ch
ic
ag
o
(c1
9) 
“T
he
 pr
ob
lem
 w
ith
 th
at 
is 
the
y 
on
ly
 h
av
e 
a 
ce
rt
ai
n 
am
ou
nt
 o
f t
im
e 
fo
r y
ou
—
pe
rio
d.
 
A
nd
 if
 y
ou
 g
o 
in
 th
er
e 
w
ith
 a
 li
st 
of
 q
ue
sti
on
s, 
[th
e d
oc
tor
 m
igh
t s
ay
] ‘
W
el
l, 
w
e’
re
 o
nl
y 
he
re
 fo
r t
hi
s o
ne
, s
o 
w
e’
ll 
di
sc
us
s t
hi
s o
ne
. Y
o
u
 c
an
 c
o
m
e 
ba
ck
’. 
It’
s l
ik
e,
 ‘
W
el
l, 
I h
av
e 
th
es
e 
ot
he
r q
ue
sti
on
s’
. [
the
 do
cto
r m
igh
t s
ay
] ‘
W
el
l, 
I h
av
e 
o
th
er
 p
at
ie
nt
s. 
I’m
 o
n 
a 
tim
e 
sc
he
du
le
’. 
So
 th
ey
 g
o 
w
ith
 th
e 
m
os
t s
ev
er
e 
th
in
g 
an
d 
th
en
 m
ov
e 
fo
rw
ar
d.
”
Ye
s
G
en
er
al
 P
op
ul
at
io
n
30
–4
4
Sa
cr
am
en
to
A
ct
io
ns
 ta
ke
n
 a
fte
r H
CP
 d
isc
us
sio
n 
an
d 
re
as
on
s f
or
 in
ac
tio
n
(c2
0) 
“I 
alw
ay
s g
o 
ho
m
e 
[af
ter
 do
cto
r’s
 vi
sit
] a
nd
 I 
sh
are
 w
ith
 m
y h
us
ba
nd
 an
d w
e m
ak
e 
su
re
 w
e 
do
 th
e 
ch
ec
ks
 a
nd
 I 
sh
ar
e 
it 
w
ith
 m
y 
sis
te
r.”
Ye
s
A
fri
ca
n 
A
m
er
ic
an
30
–4
4
B
irm
in
gh
am
(c2
1) 
“M
m-
hm
m 
[re
ce
ive
d 
m
am
m
og
ra
m
s] 
M
y t
wo
 s
ist
er
s (
the
 on
e i
s 2
3, 
an
d t
he
 ot
he
r 
o
n
e’
s 
25
) a
nd
 m
e.”
Ye
s
A
fri
ca
n 
A
m
er
ic
an
18
–2
9
B
irm
in
gh
am
(c2
2) 
“S
o I
 fo
llo
w
 [t
he
 H
CP
’s]
 pl
an
, w
hic
h i
s p
ro
ba
bly
 fiv
e 
to
 te
n 
ye
ar
s e
ar
lie
r t
ha
n 
yo
u 
w
o
u
ld
 n
or
m
al
ly
 d
o 
so
m
e 
of
 th
es
e 
[sc
ree
nin
g t
es
ts 
fo
r c
an
ce
r].
”
Ye
s
A
sh
ke
n
az
i J
ew
ish
30
–4
4
Ch
ic
ag
o
(c2
3) 
“A
t th
e e
nd
 of
 ou
r v
isi
t, h
e (
do
cto
r) 
ba
sic
all
y j
ust
 sa
t m
e i
n h
is 
roo
m 
an
d s
aid
, 
‘
Th
er
e’
s t
hi
s n
ew
 te
st
’. 
Th
is 
w
as
 a
bo
ut
 fo
ur
 y
ea
rs
 a
go
. I
 g
ue
ss
 it
 w
as
 a
 h
ot
 to
pi
c 
th
en
. H
e 
ga
v
e 
m
e 
a 
pa
m
ph
le
t a
nd
 sa
id
 ‘W
o
u
ld
 y
ou
 b
e 
in
te
re
ste
d 
in
 ta
ki
ng
 th
is?
 H
er
e’
s a
 fo
rm
 to
 fi
ll 
o
u
t i
f y
ou
 w
an
t t
o 
go
 fo
r t
es
tin
g’
. I
 d
id
n’
t d
o 
an
yt
hi
ng
 w
ith
 it
. [
Th
e p
am
ph
let
 m
en
tio
ne
d 
fe
rti
lit
y 
an
d 
th
e 
pr
ed
isp
os
iti
on
 fo
r B
RC
A 
ge
ne
 m
ut
at
io
n]
. I
 di
dn
’t 
wa
n
t t
o 
ch
op
 o
ff 
m
y 
bo
ob
s. 
I d
id
n’
t w
an
t t
o 
th
in
k 
ab
ou
t i
t t
oo
 m
uc
h.
 H
e’
s l
ik
e 
‘Y
o
u
 c
an
 k
no
w
,
 
o
r 
yo
u 
ca
nn
ot
 
kn
ow
’.
 I’
m
 li
ke
 ‘
I’
ll 
ch
oo
se
 n
ot
 k
no
w
in
g 
if 
I h
av
e 
it 
or
 n
ot
’.”
N
o
A
sh
ke
n
az
i J
ew
ish
30
–4
4
N
ew
 Y
o
rk
a F
am
ily
 h
ist
or
y 
re
fe
rs
 to
 a
ny
 h
ist
or
y 
of
 b
re
as
t a
nd
 o
v
ar
ia
n 
ca
nc
er
.
H
B
O
C,
 h
er
ed
ita
ry
 b
re
as
t a
nd
 o
v
ar
ia
n 
ca
nc
er
; H
CP
,
 
he
al
th
ca
re
 p
ro
v
id
er
.
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